Nuclear Medicine Market : Forecast to 2024-2032
| 出版年月 | 2024年5月 |
| ページ数 | 169 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,850 |
| 種別 | 英文調査報告書 |
Report Overview
Growth Factors of Nuclear Medicine Market
The nuclear medicine market size was valued at USD 7.53 billion in 2022, and the market is now projected to grow from USD 8.42 billion in 2023 to USD 29.35 billion by 2030, exhibiting a CAGR of 19.5% during the forecast period of 2023-2030.
The COVID-19 pandemic hindered marketplace revenue in 2020 due to a decline in diagnostic strategies like PET-CT and SPECT. Challenges blanketed staff shortages, transmission risks, and disruptions in supply chains and logistics, complicating the renovation of protection precautions at diagnostic facilities.
Technological improvements in nuclear imaging, particularly PET/PET-CT, are driving market boom via expanding applications past oncology to cardiology, neurology, and infection detection. Increased focus of the advantages of early prognosis and its effect on dealing with persistent issues in addition propels market improvement.
Robust pipelines in nuclear medicine therapies are boosting marketplace boom, pushed by their superior medical effects in comparison to different remedies. The increasing sophistication of therapeutic packages and successful effects in treating cancer and different issues are predicted to decorate call for, particularly in countries with high cancer fees.
Comprehensive Analysis of Nuclear Medicine Market
The nuclear medicine market growth is rising at an exponential rate due to its market segmentation. This marketplace enlargement successfully affords an in-depth local exam thinking about the dominant deliver and demand forces that effect the enterprise. These segmentations are methodically segregated by type analysis, by application analysis, by end-user analysis. By type analysis include, PET radiopharmaceuticals and SPECT radiopharmaceuticals. Further, the PET is segmented into FDG-PET/18F, 68Ga, 68Cu, 11C, and others. By application analysis include, neurology, cardiology, oncology, and others. By end-user analysis include, hospitals & clinics, diagnostic centers, and others.
The North America region lead the nuclear medicine market share by benefitting a market size of USD 3.87 billion in 2022 due to increasing usage of technologically advanced and efficient therapeutic radiopharmaceuticals across the region.
The pinnacle players inside the market play a critical function in the enterprise assuring market growth and placing marketplace requirements. These players include, Lantheus Medical Imaging (U.S.), Cardinal Health (U.S.), Norgine B.V. (Netherlands), Nordion (Canada), Bayer AG (Germany), Curium (France), Advanced Accelerator Applications (Novartis AG) (France), Bracco Diagnostic Inc. (U.S.), Jubilant Pharmova Limited (India), and GE Healthcare (U.S.) these market players provide a level-playing competitive landscape.
In February 2023, Telix Pharmaceuticals Limited, in collaboration with Heidelberg University Hospital, successfully completed a research project in February 2021 to develop a generator-based theranostic compound targeting PSMA for urologic oncology using the beta-emitting isotope rhenium-188 (188Re).
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2030
Base Year 2022
Estimated Year 2023
Forecast Period 2023-2030
Historical Period 2019-2021
Growth Rate CAGR of 19.5% from 2023-2030
Unit Value (USD billion)
Segmentation By Type, By Application, By End-user, and By Region
By Type
• Diagnostic
o PET Radiopharmaceuticals
• FDG-PET/18F
• 68Ga
• 68Cu
• 11C
• Others
o SPECT Radiopharmaceuticals
• Technetium-99m
• Iodine-123
• Xenon-133
• Thallium-201
• Others
• Therapeutic
By Application
• Neurology
• Cardiology
• Oncology
• Others
By End-user
• Hospitals & Clinics
• Diagnostic Centers
• Others
By Region
• North America (By Type, By Application, By End-user, By Country/ Sub-Region)
o U.S.
o Canada
• Europe (By Type, By Application, By End-user, By Country/ Sub-Region)
o U.K.
o Germany
o France
o Italy
o Spain
o Rest of Europe
• Asia Pacific (By Type, By Application, By End-user, By Country/ Sub-Region)
o Japan
o China
o India
o Australia
o Rest of Asia Pacific
• Rest of the World (By Type, By Application, By End-user, By Country/ Sub-Region)
Table of Contents
1. Introduction
1.1. Market Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Installed Base of PET/PET-CT Scanners – For Key Countries
4.2. Installed Base of Gamma Cameras – For Key Countries
4.3. PET/PET-CT Procedure Volume –for Key Countries
4.4. Reimbursement Scenario- For Key Countries
4.5. Key Industry Developments, Mergers, Acquisitions, New Product Launches, etc.
4.6. Pipeline Analysis, Key Players
4.7. Impact of COVID-19 on the Market
5. Global Nuclear Medicine Market Analysis, Insights and Forecast, 2019-2030
5.1. Market Analysis, Insights and Forecast – By Type
5.1.1. Diagnostic
5.1.1.1. PET Radiopharmaceuticals
5.1.1.1.1. FDG-PET/18F
5.1.1.1.2. 68Ga
5.1.1.1.3. 68Cu
5.1.1.1.4. 11C
5.1.1.1.5. Others
5.1.1.2. SPECT Radiopharmaceuticals
5.1.1.2.1. Technetium-99m
5.1.1.2.2. Iodine-123
5.1.1.2.3. Xenon-133
5.1.1.2.4. Thallium-201
5.1.1.2.5. Others
5.1.2. Therapeutic
5.2. Market Analysis, Insights and Forecast – By Application
5.2.1. Neurology
5.2.2. Cardiology
5.2.3. Oncology
5.2.4. Others
5.3. Market Analysis, Insights and Forecast – By End-user
5.3.1. Hospitals & Clinics
5.3.2. Diagnostic Centers
5.3.3. Others
5.4. Market Analysis, Insights and Forecast – By End-user
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Rest of the World
6. North America Nuclear Medicine Market Analysis, Insights and Forecast, 2019-2030
6.1. Market Analysis, Insights and Forecast – By Type
6.1.1. Diagnostic
6.1.1.1. PET Radiopharmaceuticals
6.1.1.1.1. FDG-PET/18F
6.1.1.1.2. 68Ga
6.1.1.1.3. 68Cu
6.1.1.1.4. 11C
6.1.1.1.5. Others
6.1.1.2. SPECT Radiopharmaceuticals
6.1.1.2.1. Technetium-99m
6.1.1.2.2. Iodine-123
6.1.1.2.3. Xenon-133
6.1.1.2.4. Thallium-201
6.1.1.2.5. Others
6.1.2. Therapeutic
6.2. Market Analysis, Insights and Forecast – By Application
6.2.1. Neurology
6.2.2. Cardiology
6.2.3. Oncology
6.2.4. Others
6.3. Market Analysis, Insights and Forecast – By End-user
6.3.1. Hospitals & Clinics
6.3.2. Diagnostic Centers
6.3.3. Others
6.4. Market Analysis, Insights and Forecast – By Country
6.4.1. U.S.
6.4.2. Canada
7. Europe Nuclear Medicine Market Analysis, Insights and Forecast, 2019-2030
7.1. Market Analysis, Insights and Forecast – By Type
7.1.1. Diagnostic
7.1.1.1. PET Radiopharmaceuticals
7.1.1.1.1. FDG-PET/18F
7.1.1.1.2. 68Ga
7.1.1.1.3. 68Cu
7.1.1.1.4. 11C
7.1.1.1.5. Others
7.1.1.2. SPECT Radiopharmaceuticals
7.1.1.2.1. Technetium-99m
7.1.1.2.2. Iodine-123
7.1.1.2.3. Xenon-133
7.1.1.2.4. Thallium-201
7.1.1.2.5. Others
7.1.2. Therapeutic
7.2. Market Analysis, Insights and Forecast – By Application
7.2.1. Neurology
7.2.2. Cardiology
7.2.3. Oncology
7.2.4. Others
7.3. Market Analysis, Insights and Forecast – By End-user
7.3.1. Hospitals & Clinics
7.3.2. Diagnostic Centers
7.3.3. Others
7.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Spain
7.4.5. Italy
7.4.6. Scandinavia
7.4.7. Rest of Europe
8. Asia Pacific Nuclear Medicine Market Analysis, Insights and Forecast, 2019-2030
8.1. Market Analysis, Insights and Forecast – By Type
8.1.1. Diagnostic
8.1.1.1. PET Radiopharmaceuticals
8.1.1.1.1. FDG-PET/18F
8.1.1.1.2. 68Ga
8.1.1.1.3. 68Cu
8.1.1.1.4. 11C
8.1.1.1.5. Others
8.1.1.2. SPECT Radiopharmaceuticals
8.1.1.2.1. Technetium-99m
8.1.1.2.2. Iodine-123
8.1.1.2.3. Xenon-133
8.1.1.2.4. Thallium-201
8.1.1.2.5. Others
8.1.2. Therapeutic
8.2. Market Analysis, Insights and Forecast – By Application
8.2.1. Neurology
8.2.2. Cardiology
8.2.3. Oncology
8.2.4. Others
8.3. Market Analysis, Insights and Forecast – By End-user
8.3.1. Hospitals & Clinics
8.3.2. Diagnostic Centers
8.3.3. Others
8.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. Southeast Asia
8.4.6. Rest of Asia Pacific
9. Rest of the World Nuclear Medicine Market Analysis, Insights and Forecast, 2019-2030
9.1. Market Analysis, Insights and Forecast – By Type
9.1.1. Diagnostic
9.1.1.1. PET Radiopharmaceuticals
9.1.1.1.1. FDG-PET/18F
9.1.1.1.2. 68Ga
9.1.1.1.3. 68Cu
9.1.1.1.4. 11C
9.1.1.1.5. Others
9.1.1.2. SPECT Radiopharmaceuticals
9.1.1.2.1. Technetium-99m
9.1.1.2.2. Iodine-123
9.1.1.2.3. Xenon-133
9.1.1.2.4. Thallium-201
9.1.1.2.5. Others
9.1.2. Therapeutic
9.2. Market Analysis, Insights and Forecast – By Application
9.2.1. Neurology
9.2.2. Cardiology
9.2.3. Oncology
9.2.4. Others
9.3. Market Analysis, Insights and Forecast – By End-user
9.3.1. Hospitals & Clinics
9.3.2. Diagnostic Centers
9.3.3. Others
10. Competitive Analysis
10.1. Global Market Share Analysis (2022)
10.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
10.2.1. Lantheus Medical Imaging, Inc.
10.2.1.1. Overview,
10.2.1.2. Products,
10.2.1.3. SWOT Analysis,
10.2.1.4. Recent Developments,
10.2.1.5. Strategies,
10.2.1.6. Financials (Based on Availability)
10.2.2. Cardinal Health
10.2.2.1. Overview,
10.2.2.2. Products,
10.2.2.3. SWOT Analysis,
10.2.2.4. Recent Developments,
10.2.2.5. Strategies,
10.2.2.6. Financials (Based on Availability)
10.2.3. Norgine B.V.
10.2.3.1. Overview,
10.2.3.2. Products,
10.2.3.3. SWOT Analysis,
10.2.3.4. Recent Developments,
10.2.3.5. Strategies,
10.2.3.6. Financials (Based on Availability)
10.2.4. Nordion (Canada) Inc.
10.2.4.1. Overview,
10.2.4.2. Products,
10.2.4.3. SWOT Analysis,
10.2.4.4. Recent Developments,
10.2.4.5. Strategies,
10.2.4.6. Financials (Based on Availability)
10.2.5. Bayer AG
10.2.5.1. Overview,
10.2.5.2. Products,
10.2.5.3. SWOT Analysis,
10.2.5.4. Recent Developments,
10.2.5.5. Strategies,
10.2.5.6. Financials (Based on Availability)
10.2.6. Curium
10.2.6.1. Overview,
10.2.6.2. Products,
10.2.6.3. SWOT Analysis,
10.2.6.4. Recent Developments,
10.2.6.5. Strategies,
10.2.6.6. Financials (Based on Availability)
10.2.7. Advanced Accelerator Applications (Novartis AG)
10.2.7.1. Overview,
10.2.7.2. Products,
10.2.7.3. SWOT Analysis,
10.2.7.4. Recent Developments,
10.2.7.5. Strategies,
10.2.7.6. Financials (Based on Availability)
10.2.8. Bracco Diagnostic Inc.
10.2.8.1. Overview,
10.2.8.2. Products,
10.2.8.3. SWOT Analysis,
10.2.8.4. Recent Developments,
10.2.8.5. Strategies,
10.2.8.6. Financials (Based on Availability)
10.2.9. Jubilant Pharmova Limited
10.2.9.1. Overview,
10.2.9.2. Products,
10.2.9.3. SWOT Analysis,
10.2.9.4. Recent Developments,
10.2.9.5. Strategies,
10.2.9.6. Financials (Based on Availability)
10.2.10. GE Healthcare (General Electric Company) (U.S.)
10.2.10.1. Overview,
10.2.10.2. Products,
10.2.10.3. SWOT Analysis,
10.2.10.4. Recent Developments,
10.2.10.5. Strategies,
10.2.10.6. Financials (Based on Availability)
Fortune Business Insights（フォーチュンビジネスインサイツ）は多様な産業を対象に市場調査を行い、市場動向、競争環境、将来予測などを盛り込んだ市場調査レポートを出版しています。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
| シングルユーザ | マルチユーザ | エンタープライズ |
| USD4,850 | USD5,850 | USD6,850 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 提供ファイル：印刷不可PDF
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 提供ファイル：印刷不可PDF＋Excel
- 同一企業内6名までレポートファイルのご共有が可能です。
- エンタープライズライセンス
- 提供ファイル：印刷可能PDF＋Excel
- 同一企業内人数無制限でレポートファイルのご共有が可能です。
- シングルユーザライセンス
- 納品方法
- Eメール
- 納期
- レポートタイトルにより異なります。詳細はお気軽にお問い合わせください。
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはFortune Business Insightsの日本の販売代理店として、Fortune Business Insightsのレポートを取り扱っております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にSEMABIZまでご連絡ください。
最新調査レポート